Format

Send to

Choose Destination
Clin Immunol. 2013 Dec;149(3):339-44. doi: 10.1016/j.clim.2013.02.020. Epub 2013 Mar 5.

Targeting the trimolecular complex.

Author information

1
Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, 1775 Aurora Court, MS A140, Aurora, CO 80045, USA. Electronic address: Aaron.Michels@ucdenver.edu.

Abstract

Class II major histocompatibility molecules (MHC) confer disease risk for multiple autoimmune disorders including type 1 diabetes. The interaction between the components of the trimolecular complex (CD4(+) T cell receptors, self-peptide, and MHC class II molecules) plays a pivotal role in autoimmune disease pathogenesis. The development of therapies targeting various components of the trimolecular complex for the prevention of type 1 diabetes is actively being pursued. This review focuses on the components of the anti-insulin trimolecular complex, registers of insulin peptide binding to 'diabetogenic' MHC class II molecules, and therapies targeting each component of the trimolecular complex.

KEYWORDS:

Antigen presentation; Autoimmunity;; Autoreactive T cells;; Diabetes;; Immune therapies;; Insulin;; NOD; T cell receptor; T1D; TCR; nonobese diabetic mouse.; type 1 diabetes

PMID:
23537861
PMCID:
PMC3700599
DOI:
10.1016/j.clim.2013.02.020
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center